Abstract
Thirty-six patients with bone metastases included in a trial of supportive calcitonin on the treatment response to systemic therapy were monitored by conventional radiography, conventional indicators of bone metabolism [alkaline phosphatase (AP), osteocalcin (gla), urinary hydroxyproline excretion (OHP), urinary calcium (uCa), serum calcium (sCa)] and collagen metabolites (ICTP, the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen; PICP, the carboxy-terminal propeptide of type I procollagen; and PIIINP the amino-terminal propeptide of type III procollagen). All patients had been on the same systemic treatment for at least 3 months at the start of the trial. There was a positive correlation between the concentrations of ICTP and PICP at baseline (Spearman's rank-order correlation coefficient rs = 0.62). Both ICTP and PICP showed statistically significant correlations to the other markers of bone metabolism (except sCa and uCa) as well as to the number of bone metastases on bone scans. Reduction in ICTP correlated significantly with the treatment response at three months (rs = - 0.57). while PICP showed a borderline negative correlation to therapy response (rs = - 0.37). Of all the biochemical parameters studied the changes in ICTP showed the best correlation with the treatment response. PICP and ICTP changes in patients with progressive disease differed significantly from those in patients with responding and stable metastases, whereas no difference was found between responders and stable patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blomqvist, C., Risteli, L., Risteli, J. et al. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer 73, 1074–1079 (1996). https://doi.org/10.1038/bjc.1996.207
Issue Date:
DOI: https://doi.org/10.1038/bjc.1996.207
This article is cited by
-
Gold nanoparticles with surface-anchored chiral poly(acryloyl-L(D)-valine) induce differential response on mesenchymal stem cell osteogenesis
Nano Research (2016)
-
Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622
Breast Cancer Research and Treatment (2016)
-
Evaluation of the clinical value of bone metabolic parameters for the screening of osseous metastases compared to bone scintigraphy
BMC Nuclear Medicine (2004)
-
Bone metabolic markers in bisphosphonate therapy for skeletal metastases in patients with breast cancer
Breast Cancer (2003)
-
Bone metabolic markers as gauges of metastasis to bone: a review
Annals of Nuclear Medicine (2002)